It's on the expensive end if you're just looking at sales
But take into account the growth rate, cashflow breakeven, they own the IP, c.+60% PCP sales growth in just Australia with expansion beginning.
Yes, it's expensive on paper but there's little need for capital raising (though I think they will still raise at some point) which only leaves on-market buying if you're an institution or fund, with more than 1 years vision, wanting a piece
It's on the expensive end if you're just looking at...
Add BIO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
-0.020(6.67%) |
Mkt cap ! $59.59M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 31.5¢ | 28.0¢ | $165.2K | 551.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 79547 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 13662 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
28.5¢ |
Change
-0.020 ( 3.49 %) |
||||
| Open | High | Low | Volume | ||
| 30.5¢ | 31.5¢ | 28.0¢ | 323138 | ||
| Last updated 15.52pm 03/05/2024 ? | |||||
| BIO (ASX) Chart |